88791-12-2

Upstream product

• 88791-08-6 7-methoxybenzothiophene 
• 88791-16-6 4-bromo-7-methoxybenzothiophene-2-carboxylic acid 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 
• 88791-07-5 7-methoxybenzothiophene-2-carboxylic acid 
• 88791-15-5 β-(2-bromo-5-methoxyphenyl)-α-mercaptoacrylic acid 
• 88791-13-3 7-methoxy-4-nitrobenzothiophene 
• 88791-14-4 5-(2-bromo-5-methoxybenzylidene)rhodanine 
• 88791-04-2 S-(2-formyl-6-methoxyphenyl)-N,N-dimethylthiocarbamate 
• 88791-03-1 O-(2-formyl-6-methoxyphenyl)-N,N-dimethylthiocarbamate 
• 88791-06-4 (2-formyl-6-methoxyphenylthio)acetic acid 
• 88791-05-3 2-mercapto-3-methoxybenzaldehyde 
• 7507-86-0 2-bromo-5-methoxy-benzaldehyde 
• 344754-73-0 7-Methoxy-benzo[b]thiophen-4-ylamine 

Downstream Products

• 1312610-01-7 C₁₆H₁₄O₂S 
• 1312610-02-8 C₁₄H₁₀O₂S 
• 1312610-03-9 C₁₆H₈F₆O₆S₃ 
• 1312610-04-0 C₂₆H₃₂B₂O₄S 
• 1312610-05-1 C₃₈H₄₄N₆O₄S 
• 1312610-06-2 C₂₈H₂₈N₆S 
• 1312608-58-4 C₄₂H₅₀N₈O₆S 
• 1312610-28-8 C₁₇H₁₆O₂S 
• 1312610-29-9 C₁₅H₁₂O₂S 
• 1312610-30-2 C₁₇H₁₀F₆O₆S₃ 
• 1312610-31-3 C₂₇H₃₄B₂O₄S 
• 1312610-32-4 C₃₉H₄₆N₆O₄S 
• 1312608-59-5 C₄₃H₅₂N₈O₆S 

Relevant academic research and scientific papers

NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS

The present invention relates to a 9-azabicyclo[3.3.1]nonane derivative of formula (I), wherein R1 is H or C1-5alkyl; X is O or NR2, wherein R2 is H, C1-5alkyl or C2-5acyl and Ar is C6-10aryl or a 5-10 membered heteroaryl ring system, both being optionally substituted with one to three of R3-R5 independently selected from halogen, C1-5alkyl, C1-5alkoxy, C3-6cycloalkyl, C2-5alkenyl, C2-5alkynyl, CN, NO2, hydroxy, phenyl, phenoxy and phenylC1-2alkoxy, wherein said C1-5alkyl and C1-5alkoxy are optionally substituted with one to three halogens and wherein said phenyl, phenoxy and phenylC1-2alkoxy are optionally substituted with one to three substituents independently selected from halogen and methyl or two of R3-R5 at adjacent positions together form a methylenedioxy or propylene unit, with the proviso that the compounds exo-9-methyl-3-phenoxy-9-azabicyclo[3.3.1]nonane and N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H indazole-5-amine are excluded, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 9-azabicyclo[3.3.1]nonane derivatives and to their use in therapy.

7-Substituted Benzothiophenes and 1,2-Benzisothiazoles. Part 1. Hydroxy- or Methoxy-derivatives

Readily available 2-hydroxy-3-methoxybenzaldehyde (orthovanilin) is converted, via terminal rearrangement (Newman-Kwart) of the O-aryl-NN-dimethylthiocarbamate, into 2-mercapto-3-methoxybenzaldehyde (3).This thiol undergoes base-catalysed condensation wit